Pharmaceuticals

Citations to U.S. patents by U.S. patents granted in 2023

Other WIPO fields: [ Computer technology  |  Digital communication  |  Electrical machinery, apparatus, energy  |  Measurement  |  Audio-visual technology  |  Medical technology  |  Optics  |  Transport  |  Semiconductors  |  Telecommunications  |  Other special machines  |  Pharmaceuticals  |  Organic fine chemistry  |  Mechanical elements  |  Chemical engineering  |  Engines, pumps, turbines  |  Civil engineering  |  Control  |  Basic materials chemistry  |  Handling  |  Furniture, games  |  Machine tools  |  Biotechnology  |  Other consumer goods  |  Macromolecular chemistry, polymers  |  IT methods for management  |  Textile and paper machines  |  Basic communication processes  |  Surface technology, coating  |  Materials, metallurgy  |  Environmental technology  |  Thermal processes and apparatus  |  Analysis of biological materials  |  Food chemistry  |  Micro-structural and nano-technology ]

  *1. 11 10487332    Immunisation of large mammals with low doses of RNA
  Inventors:  Andrew Geall

  2. (1) 10 5595756    Liposomal compositions for enhanced retention of bioactive agents
  Inventors:  Marcel B. Bally; Nancy L. Boman; Pieter R. Cullis; Lawrence D. Mayer

  2. (2) 10 6180370    Humanized immunoglobulins and methods of making the same
  Inventors:  Cary L. Queen; Harold E. Selick

  2. (3) 10 9334331    Bispecific antibodies
  Inventors:  Tomoyuki Igawa; Zenjiro Sampei; Tetsuo Kojima; Tetsuhiro Soeda; Atsushi Muto; Takehisa Kitazawa; Yukiko Nishida; Chifumi Imai; Tsukasa Suzuki; Kazutaka Yoshihashi

  *2. 10 10532067    Delivery of RNA to trigger multiple immune pathways
  Inventors:  Andrew Geall; Katrin Ramsauer; Gillis Otten; Christian Walter Mandl

  *2. 10 9770463    Delivery of RNA to different cell types
  Inventors:  Andrew Geall; Katrin Ramsauer; Gillis Otten; Christian Mandl

  *2. 10 9801897    Delivery of RNA to trigger multiple immune pathways
  Inventors:  Andrew Geall; Katrin Ramsauer; Gillis Otten; Christian Mandl

  8. (9) 9 10421807    Interleukin-31 monoclonal antibody
  Inventors:  Andrea Joy Gonzales; Gregory Fici; Gary Francis Bammert; Steven Alan Dunham

  *9. 8 7557200    Superior molecular vaccine based on self-replicating RNA, suicidal DNA or naked DNA vector, that links antigen with polypeptide that promotes antigen presentation
  Inventors:  Tzyy-Choou Wu; Chien-Fu Hung

  *10. 7 10934356    Checkpoint blockade and microsatellite instability
  Inventors:  Luis Diaz; Bert Vogelstein; Kenneth W. Kinzler; Nickolas Papadopoulos; Dung Le; Drew M. Pardoll; Suzanne L. Topalian

  1. (1) 204 4816567    Recombinant immunoglobin preparations
  Inventors:  Shmuel Cabilly; Herbert L. Heyneker; William E. Holmes; Arthur D. Riggs; Ronald B. Wetzel

  2. (2) 124 5585089    Humanized immunoglobulins
  Inventors:  Cary L. Queen; Harold E. Selick

  3. (3) 103 8008449    Human monoclonal antibodies to programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
  Inventors:  Alan J. Korman; Mohan Srinivasan; Changyu Wang; Mark J. Selby; Bingliana Chen; Josephine M. Cardarelli

  3. (6) 103 5225539    Recombinant altered antibodies and methods of making altered antibodies
  Inventors:  Gregory P. Winter

  5. (8) 102 6737056    Polypeptide variants with altered effector function
  Inventors:  Leonard Presta

  *6. 99 5624821    Antibodies with altered effector functions
  Inventors:  Gregory P. Winter; Alexander R. Duncan; Dennis R. Burton

  *7. 89 5648260    DNA encoding antibodies with altered effector functions
  Inventors:  Gregory Paul Winter; Alexander Robert Duncan; Dennis Raymond Burton

  8. (4) 86 5545806    [T]Ransgenic non-human animals for producing heterologous antibodies
  Inventors:  Nils Lonberg; Robert M. Kay

  9. (9) 83 5821337    Immunoglobulin variants
  Inventors:  Paul J. Carter; Leonard G. Presta

  *9. 83 4522811    Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
  Inventors:  Deborah A. Eppstein; Elizabeth B. Fraser-Smith; Thomas R. Matthews

  *9. 83 4946778    Single polypeptide chain binding molecules
  Inventors:  Robert C. Ladner; Robert E. Bird; Karl Hardman

  *9. 83 5223409    Directed evolution of novel binding proteins
  Inventors:  Robert C. Ladner; Sonia K. Guterman; Bruce L. Roberts; William Markland; Arthur C. Ley; Rachel B. Kent

Immunotherapy Dominates: A significant portion of the top cited patents focuses on immunotherapy, highlighting its transformative impact on cancer treatment.

• US Patent No. 10934356 ("Checkpoint blockade and microsatellite instability") by Diaz et al. underscores the importance of immunotherapy combinations and the identification of predictive biomarkers for treatment response.


• US Patent No. 8008449 ("Human monoclonal antibodies to programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics") by Korman et al. highlights the impact of checkpoint inhibitors, such as anti-PD-1 antibodies, in revolutionizing cancer treatment.

• US Patent No. 10487332 ("Immunisation of large mammals with low doses of RNA") by Geall and US Patent No. 10532067 ("Delivery of RNA to trigger multiple immune pathways") by Geall et al. demonstrate the growing potential of RNA-based vaccines and therapeutic interventions.

• US Patent No. 5585089 ("Humanized immunoglobulins") by Queen et al. and US Patent No. 5225539 ("Recombinant altered antibodies and methods of making altered antibodies") by Winter highlight foundational concepts in humanizing antibodies and engineering their properties for improved therapeutic efficacy.


• US Patent No. 6737056 ("Polypeptide variants with altered effector function") by Presta and US Patent No. 5624821 ("Antibodies with altered effector functions") by Winter et al. demonstrate the importance of engineering antibody effector functions to optimize therapeutic activity and minimize side effects.


• US Patent No. 6180370 ("Humanized immunoglobulins and methods of making the same") by Queen et al. and US Patent No. 5585089 ("Humanized immunoglobulins") by Queen et al. highlight the importance of humanizing antibodies to improve their safety and efficacy.


• US Patent No. 5225539 ("Recombinant altered antibodies and methods of making altered antibodies") by Winter and US Patent No. 5624821 ("Antibodies with altered effector functions") by Winter et al. demonstrate the power of protein engineering to create novel antibody therapeutics with enhanced properties.

• US Patent No. 5595756 ("Liposomal compositions for enhanced retention of bioactive agents") by Bally et al. highlights the importance of liposomal formulations for targeted drug delivery.

Note: This article is based on the provided list of patents and may not be exhaustive.

References:
Raw data from: U.S. Patent and Trademark Office. "Data Download Tables." PatentsView. Accessed September 7, 2024. https://patentsview.org/download/data-download-tables.

Please contact me (carlos@candeloro.net) for methodology, or if you know or believe information presented is not correct.